Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 49, Issue 11, 2008, Pages 2091-2098

  Rautert, Roger ^a   Schinkothe, Timo ^b   Franklin, Jeremy ^c   Weihrauch, Martin ^a   Boll, Boris ^a   Pogge, Elke ^a   Bredenfeld, Henning ^a   Engert, Andreas ^a   Diehl, Volker ^a   Re, Daniel ^d  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^c UNIVERSITY OF COLOGNE   (Germany)

^d Centre Hospitalier Antibes Juan les Pins   (France)

Author keywords

Chemokines; Hodgkin lymphoma; Neoplasia

Indexed keywords

APRIL PROTEIN; BASIC FIBROBLAST GROWTH FACTOR; BLEOMYCIN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; LYMPHOTOXIN; PREDNISONE; PROCARBAZINE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGE; ARTICLE; BLOOD SAMPLING; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GERMANY; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNOASSAY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TREATMENT FAILURE;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHEMOKINES; CYTOKINES; FEMALE; HODGKIN DISEASE; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 57049165326     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802441339     Document Type: Article

References (31)

1. Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U. Hasenclever, D. et al. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med, 348, pp. 2386-2395.
2. Aleman, B. M., van den Belt-Dusebout, A W, Klokman, W. J., Van't Veer, M B, Bartelink, H. and van Leeuwen, F. E. (2003) Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol, 21, pp. 3431-3439.
3. Hasenclever, D. and Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med, 339, pp. 1506-1514.
4. Josting, A., Franklin, J., May, M., Koch, P., Beykirch, M. K. Heinz, J. et al. (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol, 20, pp. 221-230.
5. Re, D., Thomas, R. K., Behringer, K. and Diehl, V. (2005) From Hodgkin disease to Hodgkin lymphoma: Biologic insights and therapeutic potential. Blood, 105, pp. 4553-4560.
6. Teruya-Feldstein, J., Tosato, G. and Jaffe, E. S. (2000) The role of chemokines in Hodgkin's disease. Leuk Lymphoma, 38, pp. 363-371.
7. Maggio, E., van den Berg, A, Diepstra, A., Kluiver, J., Visser, L. and Poppema, S. (2002) Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol, 13, pp. 52-56.
8. Casasnovas, R. O., Mounier, N., Brice, P., Divine, M., Morschhauser, F. Gabarre, J. et al. (2007) Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: A study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 25, pp. 1732-1740.
9. Diehl, V., Engert, A. and Re, D. (2007) New strategies for the treatment of advanced-stage Hodgkin's lymphoma. Hematol Oncol Clin North Am, 21, pp. 897-914.
10. Pogge van Strandmann, E, Simhadri, V. R., Tresckow, B. V., Sasse, S., Reiners, K. S. Hansen, H. P. et al. (2007) Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity
11. Marshall, N. A., Christie, L. E., Munro, L. R., Culligan, D. J., Johnston, P. W. Barker, R. N. et al. (2004) Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood, 103, pp. 1755-1762.
12. Juszczynski, P., Ouyang, J., Monti, S., Rodig, S. J., Takeyama, K. Abramson, J. et al. (2007) The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA, 104, pp. 13134-13139.
13. Herbst, H., Foss, H. D., Samol, J., Araujo, I., Klotzbach, H. Krause, H. et al. (1996) Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood, 87, pp. 2918-2929.
14. Herbst, H. (1996) Epstein-Barr virus in Hodgkin's disease. Semin Cancer Biol, 7, pp. 183-189.
15. Gandhi, M. K., Tellam, J. T. and Khanna, R. (2004) Epstein-Barr virus-associated Hodgkin's lymphoma. Br J Haematol, 125, pp. 267-281.
16. Gandhi, M. K., Lambley, E., Burrows, J., Dua, U., Elliott, S. Shaw, P. J. et al. (2006) Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res, 12, pp. 460-464.
17. Bohlen, H., Kessler, M., Sextro, M., Diehl, V. and Tesch, H. (2000) Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol, 79, pp. 110-113.
18. Sarris, A. H., Kliche, K. O., Pethambaram, P., Preti, A., Tucker, S. Jackow, C. et al. (1999) Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol, 10, pp. 433-440.
19. Vassilakopoulos, T. P., Nadali, G., Angelopoulou, M. K., Siakantaris, M. P., Dimopoulou, M. N. Kontopidou, F. N. et al. (2001) Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica, 86, pp. 274-281.
20. Nadali, G., Tavecchia, L., Zanolin, E., Bonfante, V., Viviani, S. Camerini, E. et al. (1998) Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood, 91, pp. 3011-3016.
21. Weihrauch, M. R., Manzke, O., Beyer, M., Haverkamp, H., Diehl, V. Bohlen, H. et al. (2005) Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res, 65, pp. 5516-5519.
22. Fischer, M., Bijman, M., Molin, D., Cormont, F., Uyttenhove, C. van Snick, J. et al. (2003) Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma. Leukemia, 17, pp. 2513-2516.
23. Skinnider, B. F., Kapp, U. and Mak, T. W. (2002) The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma, 43, pp. 1203-1210.
24. Jundt, F., Anagnostopoulos, I., Bommert, K., Emmerich, F., Muller, G. Foss, H. D. et al. (1999) Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood, 94, pp. 2065-2071.
25. Aldinucci, D., Lorenzon, D., Cattaruzza, L., Pinto, A., Gloghini, A. Carbone, A. et al. (2008) Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer
26. Buri, C., Korner, M., Scharli, P., Cefai, D., Uguccioni, M. Mueller, C. et al. (2001) CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease. Blood, 97, pp. 1543-1548.
27. Passam, F. H., Alexandrakis, M. G., Moschandrea, J., Sfiridaki, A., Roussou, P. A. and Siafakas, N. M. (2006) Angiogenic molecules in Hodgkin's disease: Results from sequential serum analysis. Int J Immunopathol Pharmacol, 19, pp. 161-170.
28. Giles, F. J., Vose, J. M., Do, K. A., Johnson, M. M., Manshouri, T. Bociek, G. et al. (2004) Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res, 28, pp. 595-604.
29. Chiu, A., Xu, W., He, B., Dillon, S. R., Gross, J. A. Sievers, E. et al. (2007) Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood, 109, pp. 729-739.
30. Munro, L. R., Johnston, P. W., Marshall, N. A., Canning, S. J., Hewitt, S. G. Tveita, K. et al. (2003) Polymorphisms in the interleukin-10 and interferon gamma genes in Hodgkin lymphoma. Leuk Lymphoma, 44, pp. 2083-2088.
31. Hohaus, S., Giachelia, M., Di Febo, A, Martini, M., Massini, G. Vannata, B. et al. (2007) Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol, 18, pp. 1376-1381.